Reuters logo
BRIEF-Ligand enters into worldwide OmniAb platform license agreement with ONO Pharmaceutical
December 22, 2016 / 1:47 PM / a year ago

BRIEF-Ligand enters into worldwide OmniAb platform license agreement with ONO Pharmaceutical

Dec 22 (Reuters) - Ligand Pharmaceuticals Inc :

* ONO will be responsible for all costs related to programs

* Ligand Pharmaceuticals-co eligible for annual platform access, development milestone payments, royalties for each product incorporating Omniab antibody

* Ligand Pharmaceuticals - under license, ONO will be able to use omnirat, omnimouse and omniflicplatforms to discover fully human mono- and bispecific antibodies

* Ligand enters into worldwide OmniAb platform license agreement with ONO Pharmaceutical Co. Ltd. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below